CCND1 and lung carcinoma: An association between the cyclin D1 overexpression and therapeutic response to drugs, such as tamoxifen in breast cancer patients [64] and combined chemotherapy of erlotinib and bexarotene in lung cancer patients, was identified in clinical studies [57].